Laura E. Koman

Partner

Washington + 1.202.879.3601

Connect:

Share

Laura Koman represents health care and life sciences companies on complex regulatory and compliance matters in emerging areas.

Laura advises health systems and national provider organizations on legal, regulatory, and reimbursement structures impacting remote delivery of health care services and multijurisdictional digital health strategy. She frequently counsels clients on topics such as direct-to-consumer telemedicine and telehealth, use of AI (artificial intelligence) in the provision of health care services, controlled substance prescribing, state licensure, remote supervision, reimbursement, patient consent, and corporate practice of medicine.

Laura also represents life sciences companies conducting global clinical trials and research collaborations on emerging topics such as clinical trial diversity, the design and implementation of decentralized clinical trials, expanded patient recruitment programs, and the development of outsourcing arrangements between sponsors, CROs (contract research organizations), and site management organizations. Laura negotiates clinical trial and CRO agreements and provides support to clients engaged in life sciences M&A and other transactions.

Laura counsels clients across the health and life sciences industry on compliance program development and assessment and related health care fraud and abuse topics under the federal Anti-Kickback Statute, state fraud and abuse analogues, and the Physician Payments Sunshine Act (Open Payments).

Laura maintains an active pro bono practice and is a member of the American Health Law Association.

Experience

  • Large health system comments on telehealth updates in Medicare physician fee scheduleJones Day represented a large health system in considering impacts of and related comments to telehealth proposals in annual Medicare physician fee schedule.
  • National digital health company considers new services offering involving controlled substancesJones Day advised a national digital health company on the federal and state regulatory considerations in connection with a new services offering involving the prescription of controlled substances.
  • Sponsor of clinical trial enters into various vendor arrangements to support conduct of trialJones Day is representing a clinical trial sponsor in negotiating various clinical trial services vendor arrangements.
  • Digital health start-up focused on high performance athlete care launches in U.S.Jones Day advised a digital health start-up focused on high performance athlete care launches in connection with its U.S. launch.
  • Multinational pharmaceutical company develops new clinical trial agreement templateJones Day represented a multinational pharmaceutical company in connection with developing a new template clinical trial agreement for U.S. sites.
  • Large health system updates EMR platform to incorporate telehealth elementsJones Day advised a large health system in connection with developing a new electronic medical record platform to capture telehealth specific features.
  • Radial Equity acquires Premier Dental Products CompanyJones Day advised Radial Equity Partners in the acquisition and financing of Premier Dental Products Company, a leading developer and manufacturer of consumable dental products.
  • Multi-system CIN and ACO completes restructuring and creates new management services organizationJones Day advised a multi-system clinically integrated provider network and accountable care organization in restructuring and creation of new management services organization.
  • Riverside acquires CRIO, Inc.Jones Day advised The Riverside Company in the acquisition of CRIO, Inc., a leading provider of eSource and other eClinical software for clinical trial sites, CROs and the pharmaceutical/biotech market.
  • KKR acquires IVI-RMA GlobalJones Day acted as U.S. counsel in the €3 billion acquisition of IVI-RMA, a group specialized in assisted reproduction techniques.
  • Riverside portfolio company acquires Jupiter Life Science Consulting (Jupiter)Jones Day advised The Riverside Company in connection with the acquisition and financing by portfolio company Red Nucleus of Jupiter Life Science Consulting (Jupiter), a leading provider of commercial and market access strategies for global pharma, biotech, and medical device companies with its primary focus in rare disease, hematology/oncology, metabolic, and neurology therapeutic areas.
  • Riverside portfolio company acquires RockpointeJones Day represented The Riverside Company in connection with the acquisition by portfolio company Clinical Education Alliance (CEA) of Rockpointe, Inc., a premier healthcare education company providing accredited continuing education activities and related training for healthcare professionals.
  • Nurx merges with Thirty MadisonJones Day provided healthcare and data privacy counsel to Nurx in connection with its merger with Thirty Madison, a leading digital healthcare company operating across the U.S.
  • Riverside portfolio company acquires Medical Marketing Solutions GroupJones Day represented The Riverside Company in connection with the acquisition and financing by portfolio company Medical Marketing Solutions Group (MMSG), a leading medical education company that provides strategic services, scientific and medical communications, and operational and event management services to global biopharmaceutical companies.
  • City of Hope acquires Cancer Treatment Centers of AmericaJones Day advised City of Hope, a world-renowned, National Cancer Institute (NCI)-designated comprehensive cancer research and treatment organization, in connection with its acquisition of Cancer Treatment Centers of America, a network of oncology hospitals and outpatient care centers across the United States.
  • Misonix merges with BioventusJones Day represented Misonix, Inc. (Nasdaq: MSON) in its acquisition by Bioventus Inc. (Nasdaq: BVS).
  • PWNHealth and Home Access Health Corporation sold to Everlywell, forming Everly HealthJones Day advised PWNHealth LLC and Home Access Health Corporation in its sale to Everlywell, a leading digital health company, and forming Everly Health.
  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day advised Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • Riverside portfolio company acquires iTakeControlJones Day represented The Riverside Company in connection with the acquisition by portfolio company Red Nucleus, a premier provider of learning, performance, and process solutions for the life sciences industry, of iTakeControl, a leading provider of clinical operations and medical affairs technology and services focused on rare disease and specialty pharma.
  • Smith & Nephew acquires Extremity Orthopedics business of Integra LifeSciences Holdings Corporation for $240 millionJones Day advised Smith & Nephew plc, the global medical technology company, in its acquisition of the Extremity Orthopedics business of Integra LifeSciences Holdings Corporation (NASDAQ: IART) for $240 million on a cash and debt-free basis.
    • View All

    September 2025 Newsletters

    Innovative Insights: Legal Updates in Life Sciences | Third Quarter 2025

    August 2025 Alert

    Coming January 2026: CMS Launches AI Program to Screen Prior Authorization Requests for Treatments

    JULY 2025 Alert

    CMS Updates Kidney Care Choices Model

    June 2025 Alert

    Medicare's Innovation Center Charts New Direction: Part 3 – Drugs, Devices, and Data

    June 2025 Alert

    Medicare's Innovation Center Charts New Direction: Part 2 – Digital Health and AI

    June 2025 Alert

    Medicare's Innovation Center Charts New Direction: Part 1 - Providers

    April 2025 Newsletters

    State Attorneys General Increasing Oversight and Focus on Private Equity in Health Care Industry

    February 2025 Commentary

    DEA Releases Rules on Telemedicine Prescribing of Controlled Substances, Proposes Special Registrations

    January 2025 Commentary

    CMS's New TCET Pathway Expedites Medicare Coverage for FDA Breakthrough Devices

    December 2024 Commentary

    FDA's Digital Health Advisory Committee Discusses Total Product Lifecycle Considerations for GenAI-Enabled Devices
    View All

    Additional Publications

    • May 3, 2019
      Legal and Regulatory Issues with Teledermatology (article co-author), Current Dermatology Reports, 2019
    • May 1, 2019
      Telehealth and Its Attendant Fraud and Abuse Risks (chapter co-author), Health Law Handbook, 2019
    • December 1, 2017
      Privilege Protection in Fraud and Abuse Matters (chapter co-author), AHLA Best Practices Handbook for Advising Clients on Fraud and Abuse Issues, 2017

    Additional Speaking Engagements

    • August 1, 2019
      11th Annual mHealth and Telehealth World Summit―Addressing the Legal and Regulatory Barriers to Expand Telehealth Capabilities
    • April 14, 2019
      ATA19—Direct-to-Consumer Telemedicine – Lessons Learned and Strategies for Advancing Policy
    • March 22, 2019
      Institute on Medicare and Medicaid Payment Issues—2019 Changes to Medicare Reimbursement for Telehealth and Communication Technology Based Services
    • October 10, 2018
      AHLA Telemedicine Webinar Series—Part I: Fundamentals of Telemedicine Legal and Regulatory

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.